

Nivolumab CheckMate 057

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE




ADJUSTMENTS

Quality of life



Improved QoL

Serious and disabling adverse effects



Less serious adverse events observed

Other adjustments



Nivolumab CheckMate 057

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Locally advanced or metastatic squamous NSCLC after prior ChT

Experimental Arm: Nivolumab

Control Arm: Docetaxel

